Take a look at our new online store to purchase all IGF merchandise!! Click Here to SHOP
Click above to View Video The Ishan Gala Foundation Welcomes Dr. Giselle Sholler, M.D. from
the University of Vermont as new Medical Advisory Board MemberGiselle Sholler, M.D. - Assistant Professor of Pediatrics
Dr. Sholler received her M.D. from New York Medical College, in Valhalla NY. She was a resident in pediatrics and, subsequently, a fellow in pediatric hematology/oncology at Brown University, before coming to the University of Vermont in 2005.
Dr. Sholler's research focuses on new therapies for neuroblastoma and medulloblastoma. These neuronal tumors continue to be therapeutic challenges in pediatrics. Dr. Sholler has shown that Nifurtimox increases oxidative stress in neuroblastoma and induces cell death and decreases tumor size in xenograft models of neuroblastoma and medulloblastoma. Nifurtimox also decreases AKT phosphorylation increasing the cells sensitivity to chemotherapy. She is presently studying the mechanism of this drug, drugs effecting metabolic regulation and oxidative stress, and determining the best drugs to use in combination.
Dr. Sholler has completed a Phase I trial of nifurtimox. She has opened and is currently enrolling in a Phase II trial of nifurtimox in combination with cytoxan and topotecan for relapsed neuroblastoma and medulloblastoma patients. She will be opening this trial at other sites in collaboration with Dr. Roberts at Children's San Diego, Dr. Ferguson at St. Louis University, Dr. Zage at MD Anderson Houston, and Dr. Eslin at MD Anderson Orlando. Within this consortium she hopes to bring new therapies through research to children with relapsed neuroblastoma and medulloblastoma.
Dr. Sholler's lab is working in collaboration with Dr. Jeffrey Bond at the University of Vermont to understand the genomic differences within patients neuroblastoma cells. Understanding the specific biological profiles of patients neuroblastoma will lead to better understanding of the most effective treatment.
The Ishan Gala Foundation currently supports the following Cancer Research:
Personalized Medicine
Tumor samples from relapsed children are being developed into cell lines which we can use to test the effectiveness of agents, RNA expression analysis, morpoproteomics, and flow cytometry. These tumors have been transplanted into mice.
We have coordinated the development of a LIMS.
We have research looking at tumor-initiating cells (cancer stem cells).
We are looking at blood factors that can predict metastasis or disease progression.
Collaboration between world-class pediatric cancer programs at University of Vermont, Cornell-Weill, University of Texas, Houston, University of Michigan, Memorial Sloan-Kettering.
Fast-Tracked Medicine
Collaboration between world-class pediatric cancer programs at University of Vermont, University of Texas, Houston, University of Michigan, Memorial Sloan-Kettering, University of Iowa, Rady Children’s Hospital of San Diego, MD Anderson (Houston), MD Anderson (Orlando, Florida), University of Wisconsin, St. Louis, South Carolina (College of Charleston).
Development of clinical trials to with kid-friendly lower-toxicity profiles and with innovative agents and combinations of agents.
Research into off-the-shelf, already FDA-approved drugs that have strong anti-cancer effects to determine if they can help kids with neuroblastoma and medulloblastoma.
Vetting of ground-breaking pharmaceutical agents for the effectiveness in neuroblastoma and medulloblastoma.
Check out this video to see what your donations
to the Ishan Gala Foundation help support.
Join the Fight to Change the Future for Children with Cancer! Check out our communities online and keep up to date with events, fundraisers and research initiatives. Click the links below to join our groups:
.jpg)
